These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34324082)

  • 1. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study.
    Sato M; Inaba M; Yamada S; Emoto M; Ohno Y; Tsujimoto Y
    J Bone Miner Metab; 2021 Nov; 39(6):1082-1090. PubMed ID: 34324082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.
    Tominaga A; Wada K; Kato Y; Nishi H; Terayama Y; Okazaki K
    Osteoporos Int; 2021 Apr; 32(4):653-661. PubMed ID: 32979066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: An observational study.
    Mineta K; Nishisho T; Okada M; Kamada M; Sairyo K
    Bone; 2024 Sep; 186():117164. PubMed ID: 38871265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kato Y
    Osteoporos Int; 2021 Oct; 32(10):1999-2009. PubMed ID: 33770201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.
    Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
    Bone; 2022 Sep; 162():116480. PubMed ID: 35787482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration.
    Kobayakawa T; Miyazaki A; Kanayama Y; Hirano Y; Takahashi J; Suzuki T; Nakamura Y
    Mod Rheumatol; 2023 Jan; 33(1):96-103. PubMed ID: 35234889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.
    Saito T; Mizobuchi M; Kato T; Suzuki T; Fujiwara Y; Kanamori N; Makuuchi M; Honda H
    Calcif Tissue Int; 2023 Jan; 112(1):34-44. PubMed ID: 36287217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
    Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study.
    Inage K; Orita S; Eguchi Y; Shiga Y; Koda M; Aoki Y; Kotani T; Akazawa T; Furuya T; Nakamura J; Takahashi H; Suzuki-Narita M; Maki S; Hagiwara S; Inoue M; Norimoto M; Kinoshita H; Sato T; Sato M; Enomoto K; Takaoka H; Mizuki N; Hozumi T; Tsuchiya R; Kim G; Otagiri T; Mukaihata T; Hishiya T; Ohtori S
    Yonsei Med J; 2021 Sep; 62(9):829-835. PubMed ID: 34427069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Real-World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study.
    Inose H; Ariga A; Motoyoshi T; Fukushima K; Tomizawa S; Kato T; Takahashi K; Yoshii T; Okawa A
    JBMR Plus; 2022 Jul; 6(7):e10637. PubMed ID: 35866147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
    Hu M; Zhang Y; Guo J; Guo C; Yang X; Ma X; Xu H; Xiang S
    Front Endocrinol (Lausanne); 2023; 14():1188969. PubMed ID: 37529613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
    Nealy KL; Harris KB
    Ann Pharmacother; 2021 May; 55(5):677-686. PubMed ID: 32862655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease.
    Miyauchi A; Hamaya E; Nishi K; Tolman C; Shimauchi J
    J Bone Miner Metab; 2022 Jul; 40(4):677-687. PubMed ID: 35639174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
    Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
    Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study.
    Baek KH; Chung YS; Koh JM; Kim IJ; Kim KM; Min YK; Park KD; Dinavahi R; Maddox J; Yang W; Kim S; Lee SJ; Cho H; Lim SK
    Endocrinol Metab (Seoul); 2021 Feb; 36(1):60-69. PubMed ID: 33677928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.
    Shimizu T; Arita K; Murota E; Hiratsuka S; Fujita R; Ishizu H; Asano T; Takahashi D; Takahata M; Iwasaki N
    J Bone Miner Metab; 2021 Sep; 39(5):868-875. PubMed ID: 33847831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis.
    Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
    Clin Nutr ESPEN; 2022 Apr; 48():267-274. PubMed ID: 35331501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.